TrueMark Investments LLC Acquires 24,839 Shares of Novo Nordisk A/S $NVO

Key Points

• TrueMark Investments LLC increased its holdings in Novo Nordisk A/S by 219.6%, acquiring an additional 24,839 shares, bringing its total to 36,151 shares valued at approximately $2.5 million.
• Recent analyst ratings for Novo Nordisk have been mixed, with HSBC setting a price target of $70.00, while Rothschild & Co upgraded the stock to a buy rating and UBS downgraded it to neutral.
• Novo Nordisk A/S reported a net margin of 35.60% and a return on equity of 78.64%, with expected earnings of 3.84 EPS for the current year.

TrueMark Investments LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 219.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,151 shares of the company's stock after buying an additional 24,839 shares during the period. TrueMark Investments LLC's holdings in Novo Nordisk A/S were worth $2,495,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Unified Investment Management bought a new position in shares of Novo Nordisk A/S in the second quarter valued at $692,000. Acadian Asset Management LLC lifted its position in shares of Novo Nordisk A/S by 15,919.9% during the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company's stock valued at $72,523,000 after purchasing an additional 1,038,137 shares in the last quarter. Norden Group LLC lifted its position in shares of Novo Nordisk A/S by 216.3% during the second quarter. Norden Group LLC now owns 96,332 shares of the company's stock valued at $6,649,000 after purchasing an additional 65,877 shares in the last quarter. Guild Investment Management Inc. lifted its position in shares of Novo Nordisk A/S by 20.7% during the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company's stock valued at $2,553,000 after purchasing an additional 6,345 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of Novo Nordisk A/S by 48.7% during the second quarter. Farther Finance Advisors LLC now owns 103,138 shares of the company's stock valued at $7,119,000 after purchasing an additional 33,794 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

NVO has been the topic of a number of recent analyst reports. HSBC set a $70.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, October 1st. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a research report on Tuesday, September 16th. UBS Group lowered shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Rothschild Redb upgraded shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $76.00.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $54.41 on Friday. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $118.26. The company has a 50-day simple moving average of $56.24 and a 200 day simple moving average of $62.72. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The company has a market capitalization of $242.93 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 2.50 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. On average, research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.